Research summary, original research, 2023

Evaluation of a New Real-Time Dosimeter Sensor for Interventional Radiology Staff

Hattori K, Inaba Y, Kato T, Fujisawa M, Yasuno H, Yamada A, et al.. Sensors (Basel, Switzerland). 2023

Read the original paper

In plain language

In laboratory tests in Japan, the newer RaySafe i3 real-time staff dosimeter performed as well as or better than the older i2, with better angle response and no backscatter artifact. This is a device-performance result, not a measure of staff dose or health.

At a glance

Type of study
Original research, Dosimetry measurement study
Who was studied
Phantom or simulation (no people)
Size
n = 4 i3 dosimeters
Where
Japan
Summary based on
the full text

What it found

  • Angle dependency of the i3 was better than the i2, with sensitivity above 80% over a wide horizontal range.

    Key figures: 0 to ±75° with sensitivity >80% (horizontal)

  • Backscatter from behind the sensor nearly doubled i2 readings but did not affect the i3.

    Key figures: i2 sensitivity almost doubled at 180°

  • Tube-voltage dependency of the i3 stayed within ±20% of the ionization chamber between 50 and 110 kV.

    Key figures: <±20%

  • Both i2 and i3 under-responded by about 20% at very high dose rates, above levels expected for staff.

    Key figures: ~20% at 250 mGy/h

  • Dose linearity was excellent and batch uniformity was around 3-8% depending on conditions; i3 had a better lower detection limit than i2.

    Key figures: R2 = 1.00; batch uniformity 3.239%-8.141%

Limits to keep in mind

Laboratory bench and free-air measurements on a small number of devices from one manufacturer; no clinical staff measurements or comparison with lens dose in practice.

How this summary was made

ORSIF prepared this summary with AI assistance from the full text of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.